|
|
| (4 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Reteplase#Contraindications]] |
| {{Reteplase}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
|
| |
|
| ==Contraindications==
| | [[Category: Cardiovascular Drugs]] |
| | | [[Category: Drug]] |
| Because thrombolytic therapy increases the risk of bleeding, Retavase® is contraindicated in the following situations<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RETAVASE (RETEPLASE) KIT [EKR THERAPEUTICS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9ae6656-977c-4105-8528-bee664aab27a | publisher = | date = |accessdate = }}</ref>:
| | [[Category: Anticoagulants]] |
| | |
| '''*Active internal [[bleeding]]
| |
| *History of [[cerebrovascular accident]]
| |
| *Recent intracranial or intraspinal surgery or trauma (see [[Reteplase warnings|WARNINGS]])
| |
| *Intracranial neoplasm, [[arteriovenous malformation]], or [[aneurysm]]
| |
| *Known bleeding [[diathesis]]
| |
| *Severe uncontrolled [[hypertension]]'''<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RETAVASE (RETEPLASE) KIT [EKR THERAPEUTICS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9ae6656-977c-4105-8528-bee664aab27a | publisher = | date = |accessdate = }}</ref>:
| |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| [[Category:Cardiovascular Drugs]] | |
| [[Category:Drugs]] | |